Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062

OBJECTIVE: First-line pembrolizumab with/without chemotherapy versus chemotherapy was evaluated in programmed death ligand 1 combined positive score ≥1, locally advanced/unresectable or metastatic gastric cancer/gastrooesophageal junction cancer in the KEYNOTE-062 study. We present results for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Lee, Keun-Wook, Chung, Hyun Cheol, Lee, Jeeyun, Yamaguchi, Kensei, Chen, Jen-Shi, Yoshikawa, Takaki, Amagai, Kenji, Yeh, Kun-Huei, Goto, Masahiro, Chao, Yee, Lam, Ka-On, Han, Shi Rong, Shiratori, Shinichi, Shah, Sukrut, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991501/
https://www.ncbi.nlm.nih.gov/pubmed/36533429
http://dx.doi.org/10.1093/jjco/hyac188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991501/
https://www.ncbi.nlm.nih.gov/pubmed/36533429
http://dx.doi.org/10.1093/jjco/hyac188

Ejemplares similares